TPI [TIANYIN PHARMACEUTICAL] EFFECT: (Original Filing)

[.FormData {color: blue; background-color: white; font-size: small; font-family: Times, serif} .SmallFormData {color: blue; background-color: white; font-size: x-small; font-family: Times, serif} .FootnoteData {color: green; background-color: white; font-size: x-small; font-family: Times, serif} .FormText {font-size: x-small; font-family: arial, helvetica, sans-serif} .SmallFormText {font-size: xx-small; font-family: arial, helvetica, sans-serif} .FormTitle {font-size: medium; font-family: arial, helvetica, sans-serif; font-weight: bold} .FormName {font-size: large; font-family: arial, helvetica, sans-serif;]

By | 2016-03-27T18:15:59+00:00 July 16th, 2013|Categories: Chinese Stocks, SEC Original, TPI|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] EFFECT: .FormData {color: blue; background-color: white; font-size: small; font-family:

[.FormData {color: blue; background-color: white; font-size: small; font-family: Times, serif} .SmallFormData {color: blue; background-color: white; font-size: x-small; font-family: Times, serif} .FootnoteData {color: green; background-color: white; font-size: x-small; font-family: Times, serif} .FormText {font-size: x-small; font-family: arial, helvetica, sans-serif} .SmallFormText {font-size: xx-small; font-family: arial, helvetica, sans-serif} .FormTitle {font-size: medium; font-family: arial, helvetica, sans-serif; font-weight: bold} .FormName {font-size: large; font-family: arial, helvetica, sans-serif;]

By | 2016-03-27T18:17:03+00:00 July 16th, 2013|Categories: Chinese Stocks, TPI, Webplus ver|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] POS AM: (Original Filing)

[Post Effective Amendment No.5 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tianyin Pharmaceutical Co., Inc. Delaware (State or other jurisdiction of incorporation or organization) 20-4857782 (I.R.S. Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 Renmin Road South, Chengdu, P. R. China, 610041 +0086-28-86154737 Dr. Guoqing Jiang, Chief Executive Officer Tianyin Pharmaceutical Co.,] [HUNTER TAUBMAN WEISS LLP 130 w. 42nd Street, Suite 1050 New York, New York 10036 (212) 732-7184 Fax: (212) 202-6380 E-mail: LTaubman@htwlaw.com July 1, 2013 Tianyin Pharmaceutical Co., Inc. 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 Ladies and Gentlemen: Sincerely, HUNTER TAUBMAN WEISS LLP Louis E. Taubman EX-5.1 2 posam2013a5ex5i_tianyin.htm] [Patrizio & Zhao, LLC Certified Public Accountants and Consultants 322 Route 46 West Parsippany, NJ 07054 Fax: (973) 882-0788 www.pzcpa.com Member of Alliance of worldwide accounting firms CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the use in the Post-Effective Amendment No. 5 to a Registration Statement on Form S-1 pertaining to the registration of 12,559,099 shares of]

By | 2016-03-27T18:18:39+00:00 July 1st, 2013|Categories: Chinese Stocks, SEC Original, TPI|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] POS AM: Post Effective Amendment No.5 to FORM S-1 REGISTRATION

[Post Effective Amendment No.5 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tianyin Pharmaceutical Co., Inc. Delaware (State or other jurisdiction of incorporation or organization) 20-4857782 (I.R.S. Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 Renmin Road South, Chengdu, P. R. China, 610041 +0086-28-86154737 Dr. Guoqing Jiang, Chief Executive Officer Tianyin Pharmaceutical Co.,] [HUNTER TAUBMAN WEISS LLP 130 w. 42nd Street, Suite 1050 New York, New York 10036 (212) 732-7184 Fax: (212) 202-6380 E-mail: LTaubman@htwlaw.com July 1, 2013 Tianyin Pharmaceutical Co., Inc. 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 Ladies and Gentlemen: Sincerely, HUNTER TAUBMAN WEISS LLP Louis E. Taubman EX-5.1 2 posam2013a5ex5i_tianyin.htm] [Patrizio & Zhao, LLC Certified Public Accountants and Consultants 322 Route 46 West Parsippany, NJ 07054 Fax: (973) 882-0788 www.pzcpa.com Member of Alliance of worldwide accounting firms CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the use in the Post-Effective Amendment No. 5 to a Registration Statement on Form S-1 pertaining to the registration of 12,559,099 shares of]

By | 2016-03-27T18:19:41+00:00 July 1st, 2013|Categories: Chinese Stocks, TPI, Webplus ver|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] 8-K: (Original Filing)

[TPI Reports Third Quarter Fiscal Year 2013 Financial Results CHENGDU, China, May 14, 2013 Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for third quarter of the fiscal year 2013. Third Quarter Fiscal Year 2013 Ended March 31,] [Tianyin Pharmaceutical Co., Inc. (TPI) F3Q13 Earnings Call May 15, 2013 9:00 AM EST Operator I would now like to turn the conference over to Dr. James Tong, Chief Financial Officer. Please go ahead, sir. Dr. James Tong - Chief Financial Officer Third quarter of fiscal year 2013 financial highlights – revenue $15.5 million compared with $14.4 million in the] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT May 15, 2013 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o]

By | 2016-03-27T18:20:57+00:00 May 20th, 2013|Categories: Chinese Stocks, SEC Original, TPI|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] 8-K: TPI Reports Third Quarter Fiscal Year 2013 Financial

[TPI Reports Third Quarter Fiscal Year 2013 Financial Results CHENGDU, China, May 14, 2013 Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for third quarter of the fiscal year 2013. Third Quarter Fiscal Year 2013 Ended March 31,] [Tianyin Pharmaceutical Co., Inc. (TPI) F3Q13 Earnings Call May 15, 2013 9:00 AM EST Operator I would now like to turn the conference over to Dr. James Tong, Chief Financial Officer. Please go ahead, sir. Dr. James Tong - Chief Financial Officer Third quarter of fiscal year 2013 financial highlights – revenue $15.5 million compared with $14.4 million in the] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT May 15, 2013 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o]

By | 2016-03-27T18:22:55+00:00 May 20th, 2013|Categories: Chinese Stocks, TPI, Webplus ver|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x For the quarterly period ended March 31, 2013 o For the transition period from _______________ to _______________ Tianyin Pharmaceutical Co., Inc. Delaware (State or other jurisdiction of 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 +0086-028-86154737 (Address, including zip code, and telephone number, x o x] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2013 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James Jiayuan Tong, certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2013 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Guoqing Jiang Chief Executive Officer, Chief Accounting Officer, Chairman] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James Jiayuan Tong James Jiayuan Tong Chief Financial Officer, Director]

By | 2016-03-27T18:24:29+00:00 May 15th, 2013|Categories: Chinese Stocks, SEC Original, TPI|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] 10-Q: FORM 10-Q (Mark One) x For the quarterly

[FORM 10-Q (Mark One) x For the quarterly period ended March 31, 2013 o For the transition period from _______________ to _______________ Tianyin Pharmaceutical Co., Inc. Delaware (State or other jurisdiction of 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 +0086-028-86154737 (Address, including zip code, and telephone number, x o x] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2013 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James Jiayuan Tong, certify that: 1. I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2013 of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Guoqing Jiang Chief Executive Officer, Chief Accounting Officer, Chairman] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James Jiayuan Tong James Jiayuan Tong Chief Financial Officer, Director]

By | 2016-03-27T18:25:31+00:00 May 15th, 2013|Categories: Chinese Stocks, TPI, Webplus ver|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] 8-K: Tianyin Pharmaceutical Management Hosts Annual General Meeting May

[Tianyin Pharmaceutical Management Hosts Annual General Meeting May 8, 2013 10:00 AM ET . Operator James Jiayuan Tong - As the by-laws provide, I will act as Chairperson of the meeting. Our Corporate Secretary, Mr. Lou Taubman, will act as Secretary of the meeting. I would like to take this opportunity to introduce the directors and officers of the Company] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT May 8, 2013 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction (IRS Employer of incorporation) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o]

By | 2016-03-27T18:28:31+00:00 May 13th, 2013|Categories: Chinese Stocks, TPI, Webplus ver|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] 8-K: (Original Filing)

[Tianyin Pharmaceutical Management Hosts Annual General Meeting May 8, 2013 10:00 AM ET . Operator James Jiayuan Tong - As the by-laws provide, I will act as Chairperson of the meeting. Our Corporate Secretary, Mr. Lou Taubman, will act as Secretary of the meeting. I would like to take this opportunity to introduce the directors and officers of the Company] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT May 8, 2013 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction (IRS Employer of incorporation) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o]

By | 2016-03-27T18:26:50+00:00 May 13th, 2013|Categories: Chinese Stocks, SEC Original, TPI|Tags: , , , , , |0 Comments
Skip to toolbar